VVY — Vivoryon Therapeutics NV Income Statement
0.000.00%
Last trade - 00:00- €43.02m
- €38.23m
Annual income statement for Vivoryon Therapeutics NV, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 10.8 | 0 | -3.62 | 0 |
| Cost of Revenue | |||||
| Gross Profit | — | 9.2 | 0 | -3.1 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 16 | 23.7 | 29.1 | 25.2 | 21 |
| Operating Profit | -16 | -12.9 | -29.1 | -28.8 | -21 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -16.5 | -12.2 | -28.4 | -28.6 | -20.6 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -16.5 | -12.7 | -28.2 | -28.3 | -20.6 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -16.5 | -12.7 | -28.2 | -28.3 | -20.6 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -16.5 | -12.7 | -28.2 | -28.3 | -20.6 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.827 | -0.629 | -1.28 | -1.12 | -0.789 |